I obtained my Bachelor’s degree in Pharmaceutical Sciences and Master’s degree in Drug Sciences from the University of Basel. I completed my Master’s thesis in the Department of Systems and Molecular Toxicology, where I investigated sunitinib-induced myotoxicity and the potential role of superoxide dismutase 2 (SOD2) as a susceptibility factor.
I later joined Roche (pRED, BioX – Genetics & Genomics, Basel) for a nine-month internship, where I worked on the development and benchmarking of an approach for enriching circulating cell-free DNA (cfDNA) and DNA/RNA derived from extracellular vesicles in cerebrospinal fluid to support the identification of genomic biomarkers in neurodegenerative diseases.
In November 2024, I joined Philochem AG. Since November 2025, I have been pursuing an industrial PhD at Philochem in collaboration with IUSS Pavia within the PhD program Science and Technology for Advanced Therapies.
My research focuses on improving the therapeutic index of targeted cancer therapies. Antibody-based therapeutics represent a powerful strategy to selectively deliver bioactive molecules to the tumor microenvironment, enhancing antitumor efficacy while minimizing systemic exposure.